A key pain point with the US stocks I currently buy is that they don’t earn interest! Capital utilization is especially low, wasting resources severely.


Gate gStocks upgrade: tokenized stocks turn into “interest-earning assets.”
With a major upgrade to Gate gStocks services, five core financial functions are introduced: collateralized borrowing, a cash-yielding “Yubi Bao” feature, a unified account, leveraged trading, and stock dividends. It connects traditional US/Korean stock markets with Web3 capital rails, so idle stock assets can achieve high-efficiency liquidity and ongoing appreciation.
🌟 Key features
Collateralized borrowing: Without having to sell stocks at a loss (“cutting meat”), directly pledge your held stocks to borrow USDT, and release liquidity anytime.
Yubi Bao wealth management: Idle stock holdings can be deposited into investment products; even during consolidation periods, you can “lie back and earn” extra returns.
Unified account: Stock assets are used directly as trading margin, eliminating frequent transfers and improving capital efficiency.
Leveraged trading: Supports both long/short two-way trading and strategy bots, enabling flexible hedging and profits in both bull and bear markets.
Automatic dividends: Holdings automatically entitle you to real dividends from listed companies—no complicated operations required, and earnings are credited automatically.
💡 Why choose Gate gStocks?
Transparent underlying assets: 1:1 fully backed native stock collateral, covering US/Korean stocks and quality ETFs.
Ultra-low participation threshold: Start from 1 USDT, supports fractional-share trading, and enables buy/sell anytime, 7×24 hours a day.
View Original
post-image
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pinned